AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34948846 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 107
Study 35099263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-Based Therapy Day Hospital (MBT-DH)
Number of subjects: 114
Study 35099263 — intervention group
Group type: COMPARATOR
Intervention: Mentalization-Based Therapy Intensive Outpatient (MBT-IOP)
Number of subjects: 114
Study 34534623 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training program
Number of subjects: 27
Study 34534623 — intervention group
Group type: COMPARATOR
Intervention: Active control group (usual activities of the community service program)
Number of subjects: 27
Study 35046397 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy (CPT)
Number of subjects: 80
Study 35046397 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 80
Study 32259774 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid (ALA) 300 mg twice daily for 3 months
Number of subjects: 80
Study 32259774 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 80
Study 33924380 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian RCTs
Number of subjects: 155
Study 33924380 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian trials
Number of subjects: 155
Study 33239330 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial anaesthesia
Number of subjects: 20988
Study 33239330 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 20988
Study 36416836 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 832
Study 36416836 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab or high-dose interferon α 2b (HDI)
Number of subjects: 832
Study 36416836 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 832
Study 36416836 — intervention group
Group type: COMPARATOR
Intervention: High-dose interferon α 2b (HDI)
Number of subjects: 832
Study 33650299 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenious yeast tablet (SYT) for 6 months
Number of subjects: 90
Study 33650299 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study 32740288 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% OHP
Number of subjects: 30
Study 32740288 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% OHP
Number of subjects: 30
Study 32740288 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% DL
Number of subjects: 30
Study 32740288 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% DL
Number of subjects: 30
Study 32740288 — intervention group
Group type: COMPARATOR
Intervention: OHP
Number of subjects: 30
Study 32740288 — intervention group
Group type: EXPERIMENTAL
Intervention: DL
Number of subjects: 30
Study 32740288 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% 1RM
Number of subjects: 30
Study 32740288 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% 1RM
Number of subjects: 30
Study 33079411 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus sleeve compression/exercise intervention (lymphedema education and prevention [LEAP])
Number of subjects: 554
Study 33079411 — intervention group
Group type: COMPARATOR
Intervention: Education-only (EO)
Number of subjects: 554
Study 32939788 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA exclusion group (n = 521)
Number of subjects: 860
Study 32939788 — intervention group
Group type: COMPARATOR
Intervention: LAA nonexclusion group (n = 339)
Number of subjects: 860
Study 32939788 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA exclusion in patients with AF
Number of subjects: 860
Study 32939788 — intervention group
Group type: COMPARATOR
Intervention: LAA nonexclusion in patients without AF
Number of subjects: 860
Study 36398729 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-balloon-assisted colonoscopy (SBC)
Number of subjects: 44
Study 36398729 — intervention group
Group type: COMPARATOR
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 44
Study 34449280 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthoptic exercises
Number of subjects: 488
Study 34449280 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 488
Study 34449280 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmologists
Number of subjects: 488
Study 34449280 — intervention group
Group type: COMPARATOR
Intervention: Observation preference
Number of subjects: 488
Study 32590658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive feedback intervention
Number of subjects: 7
Study 32590658 — intervention group
Group type: COMPARATOR
Intervention: Simple feedback
Number of subjects: 7
Study 35042007 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate (BMAC) augmentation
Number of subjects: 80
Study 35042007 — intervention group
Group type: COMPARATOR
Intervention: Control (sham incision)
Number of subjects: 80
Study 34082593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cannulation
Number of subjects: 40
Study 34082593 — intervention group
Group type: COMPARATOR
Intervention: Palpation technique
Number of subjects: 40
Study 33793636 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume simethicone (1125 mg in 750 ml water)
Number of subjects: 167
Study 33793636 — intervention group
Group type: COMPARATOR
Intervention: Standard volume simethicone (300 mg in 200 ml water)
Number of subjects: 167
Study 34616010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 1039
Study 33137473 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 0
Study 32232492 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop group (2-day training course)
Number of subjects: 90
Study 32232492 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia group (educational content through video)
Number of subjects: 90
Study 32232492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training content)
Number of subjects: 90
Study 35166429 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14543
Study 32539440 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of rifampin
Number of subjects: 6841
Study 32539440 — intervention group
Group type: COMPARATOR
Intervention: 9 months of isoniazid
Number of subjects: 6841
Study 33622766 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG) treatment (up to 1,200 mg daily)
Number of subjects: 61
Study 33622766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 33622766 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG) treatment
Number of subjects: 61
Study 32992151 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone (IM) + Patient Navigation (PN)
Number of subjects: 0
Study 32992151 — intervention group
Group type: COMPARATOR
Intervention: Interim methadone (IM)
Number of subjects: 0
Study 32992151 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment-As-Usual (ETAU)
Number of subjects: 0
Study 35779610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INCS) for 3 months
Number of subjects: 134
Study 35779610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INCS) for 12 months
Number of subjects: 134
Study 35779610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 33887262 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab continued (5 mg/kg every 8 weeks)
Number of subjects: 95
Study 33887262 — intervention group
Group type: COMPARATOR
Intervention: Infliximab discontinued
Number of subjects: 95
Study 33887262 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab continued
Number of subjects: 95
Study 33887262 — intervention group
Group type: COMPARATOR
Intervention: Infliximab discontinued (retreatment)
Number of subjects: 95
Study 32479135 — intervention group
Group type: EXPERIMENTAL
Intervention: DRM02, a novel phosphodiesterase-4 inhibitor, applied topically in mouse models.
Number of subjects: 0
Study 32479135 — intervention group
Group type: EXPERIMENTAL
Intervention: DRM02, a novel phosphodiesterase-4 inhibitor, applied topically in a mouse model of psoriasis.
Number of subjects: 0
Study 32479135 — intervention group
Group type: EXPERIMENTAL
Intervention: DRM02 treatment of cultured primary human and mouse epidermal keratinocytes.
Number of subjects: 0
Study 32479135 — intervention group
Group type: EXPERIMENTAL
Intervention: DRM02 treatment of human peripheral blood mononuclear cells ex vivo and cultured THP-1 monocyte-like cells.
Number of subjects: 0
Study 32479135 — intervention group
Group type: EXPERIMENTAL
Intervention: DRM02 treatment in relation to NF-κB transcriptional activity.
Number of subjects: 0
Study 35189669 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat colonoscopy with adequate bowel preparation
Number of subjects: 651
Study 34793639 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB group (20 mL of 0.375% ropivacaine)
Number of subjects: 118
Study 34793639 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB group
Number of subjects: 118
Study 34793639 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline solution)
Number of subjects: 118
Study 34793639 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study 34793639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 118
Study 35137791 — intervention group
Group type: EXPERIMENTAL
Intervention: Himalayan Salt (HS)
Number of subjects: 17
Study 35137791 — intervention group
Group type: COMPARATOR
Intervention: Common Salt (TS)
Number of subjects: 17
Study 33305626 — intervention group
Group type: EXPERIMENTAL
Intervention: 50000 IU vitamin D weekly for 12–14 weeks
Number of subjects: 34
Study 33305626 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 34
Study 35953878 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 g/kg for men, 0.85 g/kg for women)
Number of subjects: 31
Study 35953878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 34753752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health specialist video consultations (MHSVC) in primary care
Number of subjects: 13
Study 34753752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health specialist video consultations (MHSVC)
Number of subjects: 13
Study 32843286 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestronidase alfa, rhGUS enzyme replacement therapy
Number of subjects: 0
Study 32843286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36178972 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral symptom management intervention (prototype including traditional coping skills, home-based physical activity, Acceptance and Commitment Therapy, Meaning-Centered Psychotherapy, self-compassion strategies)
Number of subjects: 31
Study 36178972 — intervention group
Group type: EXPERIMENTAL
Intervention: User testing sessions of the prototype intervention materials (paper manual and mobile application)
Number of subjects: 31
Study 34384515 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy food and drink policy implemented at scale in hospitals
Number of subjects: 4808
Study 34384515 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 4808
Study 32916985 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Calorie Mediterranean (LoCalMed)
Number of subjects: 0
Study 32916985 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study 32648260 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS relapse treatment (heterogeneous)
Number of subjects: 618
Study 32648260 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS relapse
Number of subjects: 618
Study 32648260 — intervention group
Group type: COMPARATOR
Intervention: CNS involvement at diagnosis
Number of subjects: 618
Study 32648260 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow involvement and peripheral blasts
Number of subjects: 618
Study 32469373 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Posing (experimental group): Subjects stood with hands on hips, elbows pointing out, and feet approximately 1 foot apart for 20 seconds.
Number of subjects: 0
Study 32469373 — intervention group
Group type: COMPARATOR
Intervention: Control Group: Subjects stood with hands and arms wrapping around the torso and feet together for 20 seconds.
Number of subjects: 0
Study 34864649 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol nasal spray (1 mg/d)
Number of subjects: 20
Study 34864649 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Benzalkonium chloride)
Number of subjects: 20
Study 36454906 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry (250 g)
Number of subjects: 20
Study 36454906 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 20
Study 32672508 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat specialists riding on flat (0% gradient)
Number of subjects: 19
Study 32672508 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill specialists riding uphill (6% gradient)
Number of subjects: 19
Study 35806977 — intervention group
Group type: EXPERIMENTAL
Intervention: Topographical landmarks
Number of subjects: 120
Study 35806977 — intervention group
Group type: COMPARATOR
Intervention: Radiological landmarks
Number of subjects: 120
Study 33970286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) using CT for patient selection
Number of subjects: 0
Study 33970286 — intervention group
Group type: EXPERIMENTAL
Intervention: CT combined with CT angiography (CTA) or additional perfusion imaging
Number of subjects: 0
Study 33970286 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion imaging
Number of subjects: 0
Study 33970286 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI as first-line choice
Number of subjects: 0
Study 33970286 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging with perfusion imaging
Number of subjects: 0
Study 32967713 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLAS intervention (theory-driven group-based complex intervention)
Number of subjects: 120
Study 32967713 — intervention group
Group type: COMPARATOR
Intervention: Usual individual physiotherapy (UP; pragmatic control group)
Number of subjects: 120
Study 35500513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 42
Study 35500513 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (MID)
Number of subjects: 42
Study 32891496 — intervention group
Group type: EXPERIMENTAL
Intervention: HAs featuring LFT
Number of subjects: 103
Study 32891496 — intervention group
Group type: COMPARATOR
Intervention: Conventional HAs featuring wide dynamic range compression (control group)
Number of subjects: 103
Study 32891496 — intervention group
Group type: EXPERIMENTAL
Intervention: HAs employing both LFT and wide dynamic range compression of high frequencies (combined group)
Number of subjects: 103
Study 35960070 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition white light colonoscopy (HD-WLC)
Number of subjects: 553
Study 35960070 — intervention group
Group type: COMPARATOR
Intervention: 190-narrow-band imaging (190-NBI)
Number of subjects: 553
Study 33787042 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin-containing enteral formula (Hine E-Gel®)
Number of subjects: 30
Study 33787042 — intervention group
Group type: COMPARATOR
Intervention: Standard polymeric formula (Ensure®)
Number of subjects: 30
Study 32502172 — intervention group
Group type: EXPERIMENTAL
Intervention: Persian version of The Baruth Protective Factors Inventory
Number of subjects: 200
Study 35870947 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (1 g Taurine, n = 60)
Number of subjects: 120
Study 35870947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 60)
Number of subjects: 120
Study 35340032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (anakinra for 14 days, pentoxifylline for 28 days, zinc for 180 days)
Number of subjects: 104
Study 35340032 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (methylprednisolone for 28 days)
Number of subjects: 104
Study 35340032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (anakinra, pentoxifylline, zinc)
Number of subjects: 104
Study 35340032 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (methylprednisolone)
Number of subjects: 104
Study 33514368 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine‐artesunate (PA)
Number of subjects: 1379
Study 33514368 — intervention group
Group type: COMPARATOR
Intervention: Artemether–lumefantrine (AL)
Number of subjects: 1379
Study 32167837 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric exercise
Number of subjects: 34
Study 32167837 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 34
Study 32167837 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric exercise with Blood Flow Restriction Training (BFRT)
Number of subjects: 34
Study 32167837 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise with Blood Flow Restriction Training (BFRT)
Number of subjects: 34
Study 33655650 — intervention group
Group type: EXPERIMENTAL
Intervention: InnoSEAL
Number of subjects: 606
Study 33655650 — intervention group
Group type: COMPARATOR
Intervention: PCD
Number of subjects: 606
Study 33454706 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg
Number of subjects: 246
Study 33454706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 36399081 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tooth bone powder
Number of subjects: 60
Study 36399081 — intervention group
Group type: COMPARATOR
Intervention: Inorganic bovine bone powder
Number of subjects: 60
Study 36399081 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no implants)
Number of subjects: 60
Study 33461579 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic clipping after EMR
Number of subjects: 356
Study 33461579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic clipping)
Number of subjects: 356
Study 32574181 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder designed to evoke emotional guilt
Number of subjects: 161587
Study 32574181 — intervention group
Group type: EXPERIMENTAL
Intervention: Four additional reminder formats
Number of subjects: 161587
Study 32574181 — intervention group
Group type: COMPARATOR
Intervention: Control group (generic message)
Number of subjects: 161587
Study 36317349 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 230
Study 36317349 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 230
Study 33652093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice representatives reporting knowledge and perceptions about medication shortages
Number of subjects: 600
Study 33652093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice representatives reporting missing opioid medications
Number of subjects: 600
Study 33652093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice representatives reporting disposal practices of medications after home deaths
Number of subjects: 600
Study 35998172 — intervention group
Group type: EXPERIMENTAL
Intervention: surgical mask (sm)
Number of subjects: 12
Study 35998172 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP2 mask (ffpm)
Number of subjects: 12
Study 33187916 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent apatinib and brain radiotherapy (BR)
Number of subjects: 90
Study 33187916 — intervention group
Group type: COMPARATOR
Intervention: Brain radiotherapy (BR) alone
Number of subjects: 90
Study 34255168 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics in combination with cognitive remediation therapy (AP + CR)
Number of subjects: 15
Study 34255168 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics (AP)
Number of subjects: 15
Study 32912058 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 478
Study 32912058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study 35050837 — intervention group
Group type: EXPERIMENTAL
Intervention: RVT-1601 10 mg
Number of subjects: 108
Study 35050837 — intervention group
Group type: EXPERIMENTAL
Intervention: RVT-1601 40 mg
Number of subjects: 108
Study 35050837 — intervention group
Group type: EXPERIMENTAL
Intervention: RVT-1601 80 mg
Number of subjects: 108
Study 35050837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 32221654 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (12 2 mA, 30‐min, anodal‐left, cathodal‐right prefrontal cortex)
Number of subjects: 59
Study 32221654 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 59
Study 36149171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic stabilization exercises and TENS administered once daily for approximately 30 min during acute hospitalization
Number of subjects: 31
Study 36149171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic stabilization exercises and TENS
Number of subjects: 31
Study 32937192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (24 IU)
Number of subjects: 55
Study 32937192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 32674676 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical low-flow (CLF-LG)
Number of subjects: 3511
Study 32674676 — intervention group
Group type: COMPARATOR
Intervention: High-gradient (HG)
Number of subjects: 3511
Study 32674676 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-flow (LG)
Number of subjects: 3511
Study 32674676 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical low-flow (LG)
Number of subjects: 3511
Study 36168179 — intervention group
Group type: EXPERIMENTAL
Intervention: Telementored group
Number of subjects: 37
Study 36168179 — intervention group
Group type: COMPARATOR
Intervention: Non-telementored group
Number of subjects: 37
Study 36343030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular irradiation of blood (ILIB) combined with myofunctional exercises; ILIB treatment is performed twice a week for 8 weeks.
Number of subjects: 46